跳至主要内容
临床试验/NCT00392548
NCT00392548Unknown不适用

Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence

Tel-Aviv Sourasky Medical Center1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2006年10月最近更新:
适应症

试验速览

阶段
不适用
入组人数
130
试验地点
1

研究概览

简要总结

Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy.

Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival.

详细描述

Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month after treatment

研究设计

研究类型
Observational
观察模型
Defined Population
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
  • Patient must meet the eligibility requirements for the RTOG treatment study. (If the patient is deemed retrospectively ineligible for the RTOG treatment study, the patient will likewise be ineligible for this study.)
  • Patient must sign a study-specific informed consent for RTOG 0611 prior to study entry.

排除标准

  • Patient not able to receive 6000 cGy of radiation therapy.

研究者

申办方类型
Other Gov

研究点 (1)

Loading locations...

相似试验